Small molecule antagonists of PTPmu identified by artificial intelligence-based computational screening block glioma cell migration and growth.
Source check: Needs source check. Not independent scientific confirmation.
Finding / tested result: AtomNet selected previously untested candidates; cellular assays, a phosphatase assay and a mouse tumor experiment supported glioma-active hits. Preclinical findings do not establish clinical benefit.
Technology: AtomNet neural-network virtual screening
Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.
- AI contribution
- AtomNet neural-network virtual screening is the AI method documented in the editorial source review.
- Limitation / still unknown
- The date refers to the cited version. Earlier public versions and independent replication were not systematically verified.
Evidence sources and annotation context
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
Evidence sources: https://doi.org/10.1371/journal.pone.0288980
Needs source check · editorial details
The source has not been fully checked or contains conflicting information. Independent confirmation is not assessed by this label.
Source type: paper. Paper: not linked in this catalog; this does not mean no paper exists.
Review scope and date are not recorded; source checked does not establish full-text review.
No follow-up recorded; this is not a claim that no follow-up exists. Follow-up review scope and date are not recorded. No source-supported relationships recorded.
Editorial assessment: Impact 2/5 · Validation 3/5 · Novelty 2/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.